More than 10 pharmaceutical companies intend to spin off the listing, science and technology board, GEM into a popular listing plate.

"Pharmaceutical Network Market Analysis" Health Yuan announced on the evening of August 9 that the company's holding subsidiary Lizhu Group intends to spin off its subsidiary Zhuhai Lizhu Reagent Co., Ltd. A shares listed.
after the completion of this spin-off, the equity structure of the Lizhu Group will not change, and will maintain control of Lizhu reagents.
According to the announcement, Lizhu Group's main business for pharmaceutical products research and development, production and sales, covering preparation products, raw materials and intermediates and diagnostic reagents and equipment, the company's subsidiary Lizhu reagents for the company focused on diagnostic reagents and equipment manufacturing independent business operating platform.
In addition to Lizhu Group, according to incomplete statistics, more than 10 pharmaceutical companies have announced plans to spin off subsidiaries listed so far this year, including Changchun High-new, Liaoning Chengda, Hualan Bio, Colum Pharmaceuticals, Tian Shili, Dean Diagnostics, Huabang Health and Yan'an Bikang and other pharmaceutical companies.
, and from the announcement of more than 10 pharmaceutical companies announcing the proposed spin-off of subsidiaries listed, most of the proposed spin-off subsidiaries listed on the Science and Technology Board, GEM.
, why are the spin-off subsidiaries keen on the listing of the Trolly board and gem? In the industry's view, this is mainly related to the "hard technology" label of the board, as well as the GEM "three genes and four new" positioning.
, on the one hand, the board and GEM to implement the pilot registration system, high convenience.
, on the other hand, these subsidiaries also meet the standards and positioning of listed companies by the Board and GEM.
, in terms of the business segment of the spin-off subsidiary, mainly diagnostic reagents, vaccines and other bio-innovative drugs.
, such as Lep Medical, intends to spin off its controlling subsidiary Lep Diagnostics to list on the company.
mainly engaged in in-body diagnostic reagents and equipment research and development, production and sales business.
, Changchun High-new, Liaoning Chengda, Hualan Bio and other listed companies are proposed to spin off the vaccine business independently listed.
, Changchun High-new on the evening of May 25 announced that it intends to spin off its subsidiary Baig Bio to list on the SSE Branch.
after the completion of the spin-off, Changchun High-new equity structure will not change, and still has a controlling stake in Baig Bio.
100 grams of biological main business mainly for the development, production and sale of human biological vaccines, the main products for chickenpox vaccine, human rabies vaccine, nasal influenza vaccine.
Liaoning Chengda announced on May 8 that the company's holding subsidiary, Liaoning Chengda Biological Co., Ltd., was accepted for an IPO to raise 2.04 billion yuan.
large biological products for human rabies vaccine (Vero cells), human inactivated brain vaccine (Vero cells), the profit volume is huge.
Hualan Bio announced in April that it intends to spin off hualan vaccine to list on the Shenzhen Stock Exchange's GEM after the overall change to a limited company.
the spin-off, The Bio equity structure will not change and will remain in control of the Hualan vaccine.
Hualan biological current main business involves blood products, vaccine products two blocks.
Hualan Vaccine is the operating platform of Hualan Bio's vaccine products business, which has been focusing on vaccine research and development, production and sales since its establishment in 2005.
June 30, Hualan Bio's proposed spin-off of its subsidiary Hualan Vaccines has made new progress.
reported that the Henan Securities Regulatory Commission announced on the evening of June 30, Hualan vaccine is receiving guidance from Huatai United Securities, has been the Henan Securities Regulatory Commission for the record of counseling.
the industry believes that after the new rules of spin-off and listing come to an order, listed pharmaceutical companies to spin off their business listing, is conducive to broaden financing channels, avoid risks, achieve a win-win situation.
From the announcement issued by the above-mentioned companies, it has been stated that the "spin-off listing" will help to further enhance the overall market value of the company, enhance the profitability and comprehensive competitiveness of the company and its subsidiaries, will not have a material impact on the continued operation of other business sectors, nor will it lead to changes in the company's equity structure.
note that regulators are also closely strengthening regulation.
It is understood that the next step is for the CSRC to strengthen the whole process of supervision of the break-up behavior, and crack down on market chaos such as "sloppy" spin-off, false spin-off, speculation and the concept of spin-off, as well as insider trading, market manipulation and other illegal and illegal activities.
.